BRUSSELS: A World Health Organization-led programme to ensure poorer countries get fair access to COVID-19 vaccines, tests and treatments aims to secure antiviral drugs for patients with mild symptoms for as little as $10 per course, a draft document seen by Reuters says.
Merck & Co's experimental pill molnupiravir is likely to be one of the drugs, and other drugs to treat mild patients are being developed.
The document, which outlines the goals of the Access to COVID-19 Tools Accelerator (ACT-A) until September next year, says that the programme wants to deliver about 1 billion COVID-19 tests to poorer nations, and procure drugs to treat up to 120 million patients globally, out of about 200 million new cases it estimates in the next 12 months.
The plans highlight how the WHO wants to shore up supplies of drugs and tests at a relatively low price after losing the vaccine race to wealthy nations which scooped up a huge share of the world's supplies, leaving the world's poorest countries with few shots.
A spokesperson for the ACT-A said the document, dated Oct. 13, was still a draft under consultation and declined to comment on its content before it is finalised. The document will also be sent to global leaders ahead of a G20 summit in Rome at the end of this month.
The ACT-A asks the G20 and other donors for additional funding of $22.8 billion until September 2022 which will be needed to buy and distribute vaccines, drugs and tests to poorer nations and narrow the huge gaps in supply between wealthy and less advanced countries. Donors have so far pledged $18.5 billion to the programme.
The financial requests are based on detailed estimates about the price of drugs, treatments and tests, which will account for the programme's biggest expenses alongside the cost of distributing vaccines.
Although it does not explicitly cite molnupiravir, the ACT-A document expects to pay $10 dollar per course for "novel oral antivirals for mild/moderate patients".
Other pills to treat mild patients are being developed, but molnupiravir is the only one which has so far showed positive results in late-stage trials. The ACT-A is in talks with Merck & Co and generics producers to buy the drug.
The price is very low if compared with the $700 per course that the United States has agreed to pay for 1.7 million courses of the treatment.
However, a study carried out by Harvard university estimated that molnupiravir could cost about $20 dollars if produced by generic drugmakers, with the price potentially going down to $7.7 under an optimised production.
Merck & Co. has licensing deals with eight Indian generic drugmakers.
The ACT-A document says that its target is to reach a deal by the end of November to secure the supply of an "oral outpatient drug", which it aims to be available from the first quarter of next year.
The money raised would initially be used to "support procurement of up to 28 million treatment courses for highest risk mild/moderate patients over the next 12 months, depending on product availability, clinical guidance, and volumes changing with evolution of needs," the document says, noting this volume would be secured under an advance purchase agreement.
Larger additional amounts of new oral antivirals to treat mild patients are also expected to be procured at a later stage, the document says.
Another 4.3 million courses of repurposed COVID-19 pills to treat critical patients are also expected to be purchased at a price of $28 per course, the document says, without naming any specific drug.
The ACT-A also intends to address essential medical oxygen needs of 6-8 million severe and critical patients by September 2022.
TESTS
In addition, the programme plans to invest massively in COVID-19 diagnostics in order to at least double the number of tests carried out in poorer nations, defined as low income and low-middle income countries.
Of the $22.8 billion, ACT-A plans to raise in the next 12 months, about one third and the largest share is to be spent on diagnostics, the document says.
Currently poor countries conduct on average about 50 tests per 100,000 people every day, against 750 tests in richer nations. The ACT-A wants to bring testing rates to a minimum of 100 tests per 100,000 in poorer states.
That means delivering around 1 billion tests in the next 12 months, around 10 times more than the ACT-A has procured so far, the document shows.
The largest share of diagnostics would be rapid antigen tests at a price of around $3, and only 15% would be spent to procure molecular tests, which are more accurate but take more time to deliver results and are estimated to cost around $17, including delivery costs, the document shows.
The push on tests is meant to narrow the gap between the rich and the poor, as only 0.4% of the about 3 billion tests reported across the world have been conducted in poor nations, the document says.
It would also help spot earlier possible new variants, which tend to proliferate when infections are widespread, and therefore are more likely in the countries with lower vaccination rates.
The document underlines that "vaccine access is highly inequitable with coverage ranging from 1% to over 70%, depending largely on a country's wealth."
The programme aims to vaccinate at least 70% of the eligible population in all countries by the middle of next year, in line with the WHO's goals.
Reuters
Tue Oct 19 2021
Merck & Co's experimental pill molnupiravir is likely to be one of the drugs, and other drugs to treat mild patients are being developed. - REUTERS
Iran's supreme leader says Hamas leader's death will not halt 'Axis of Resistance'
The "Axis of Resistance", built up with years of Iranian support, includes Hamas, the Lebanese Hezbollah group, the Houthi movement in Yemen, and various Shi'ite groups in Iraq and Syria.
Putin says Russia willing to seek compromises between Iran and Israel
Russia is ready to help seek compromises between arch-foes Israel and Iran, President Vladimir Putin said on Friday, saying these would be difficult but possible.
What proposals will Russia push at the BRICS summit?
The proposal is also to establish a BRICS reinsurance company to allow uninterrupted shipment of goods and key commodities between members.
Indonesia's free meals plan in the spotlight as Prabowo readies for office
Prabowo calls the programme one of the main drivers of economic growth, eventually set to add an estimated 2.5 million jobs.
Astro AWANI's revamped English news website, AWANI International, launches on Oct 21
Astro AWANI's revamped English platform delivers in-depth global news and expert analysis to keep you informed on key developments.
Israeli strikes kill 33 people in Jabalia refugee camp in Gaza, medics say
Residents of Jabalia said Israeli tanks had reached the heart of the camp after pushing through suburbs and residential districts.
Liam Payne's ex-partner calls for media restraint after 'painful' death
Cheryl Tweedy used her statement to urge the media to remember they had a seven-year-old son, Bear, who could read the reports.
Analysts: Indonesia's strong MoF leadership team to boost investor confidence
Sri Mulyani Indrawati as head of Indonesia's Ministry of Finance is expected to instil confidence among investors.
Biden offers both a carrot and a stick to Israel as his term nears an end
Israel has frequently resisted US advice and has caused political difficulties for the Biden administration.
Putin says BRICS will generate most of global economic growth
Russian President Vladimir Putin will host a summit of the group in the city of Kazan on Oct. 22-24.
ISIS Malaysia's perspective of Budget 2025
An excellent rakyat-centric budget under the overarching principle of a caring and humane economy.
Budget 2025: Record increase in STR, SARA aid initiatives
The government will provide a significant boost to the Sumbangan Tunai Rahmah (STR) and Sumbangan Asas Rahmah (SARA) initiatives next year.
Budget 2025: EPF contributions to be made mandatory for foreign workers – PM Anwar
The government plans to make it compulsory for all non-citizen workers to contribute to the Employees Provident Fund (EPF).
What policies to expect from Indonesia's new President Prabowo
Prabowo will be open to foreign investment, his aide has said, such as by offering investors management of airports and sea ports.
Budget 2025: Govt allocates RM470 mil to empower women's participation in PMKS
The Women's Leadership Apprenticeship Program will be intensified as an effort to produce more female corporate personalities.
Israel sends more troops into north Gaza, deepens raid
Residents of Jabalia in northern Gaza said Israeli tanks had reached the heart of the camp, using heavy air and ground fire.
Indonesia ramps up security ahead of Prabowo's inauguration
Prabowo Subianto will be sworn in as Indonesia's president on Sunday with Vice President-elect, Gibran Rakabuming Raka, also taking office.
Immediate allocation of RM150 mil for local authorities, DID to tackle flash floods
Datuk Seri Anwar Ibrahim said this allocation is intended to address the recent flash floods that hit the capital and several major towns.
Budget 2025: Sabah, Sarawak to continue receiving among highest allocations - PM
Sabah and Sarawak continues to be prioritised under Budget 2025, with allocations of RM6.7 billion and RM5.9 billion respectively.
NFOF will be operational in November 2024 with funding of RM1 bil
PM Anwar Ibrahim said NFOF will support venture capital fund managers to invest in startup companies with RM300 million set aside for 2025.